Cardiologic Manifestation in Amyloidosis

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
bookPart
Data de publicação
2023
DOI
Scopus
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER INTERNATIONAL PUBLISHING
Autores
SINGULANE, C. de Carvalho
Citação
de Alencar Neto, A. C.; Cafezeiro, C. R. F.; Bueno, B. V. K.; de Carvalho Singulane, C.; Fernandes, F.. Cardiologic Manifestation in Amyloidosis. In: . Amyloidosis and Fabry Disease: a Clinical Guide: SPRINGER INTERNATIONAL PUBLISHING, 2023. p.43-48.
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ATTR and AL amyloidosis are responsible for approximately 95% of all cases of CA. Cardiac amyloidosis (CA) is a relatively common cause of heart failure with preserved ejection fraction (HFpEF). It is important to know that extracardiac changes may precede cardiac involvement by a few years; thus, it is essential to recognize these findings as part of the clinical feature in a patient with amyloidosis. CA results from the progressive deposition of amyloid fibrils in the extracellular space. The involvement of amyloidosis includes mechanical and electrical manifestations. The most frequent CA clinical presentation is HFpEF with a restrictive pattern leading to diastolic dysfunction, followed by systolic dysfunction. Conduction disorders and arrhythmias are commonly associated. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.
Palavras-chave
Arrhythmias, Cardiac amyloidosis, Cardiac manifestations, Heart failure, Preserved ejection fraction
URI
https://observatorio.fm.usp.br/handle/OPI/57277
Referências
  1. Simoes M.V., Fernandes F., Marcondes-Braga F.G., Scheinberg P., Correia E.B., Rohde L.E.P., Et al., Position statement on diagnosis and treatment of cardiac Amyloidosis—2021, Arq Bras Cardiol, 117, 3, pp. 561-598, (2021)
  2. Ruberg F.L., Grogan M., Hanna M., Kelly J.W., Maurer M.S., Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review, J Am Coll Cardiol, 73, 22, pp. 2872-2891, (2019)
  3. Maurer M.S., Schwartz J.H., Gundapaneni B., Elliott P.M., Merlini G., Waddington-Cruz M., Et al., Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med, 379, 11, pp. 1007-1016, (2018)
  4. Ando Y., Coelho T., Berk J.L., Cruz M.W., Ericzon B.-G., Ikeda S.-I., Et al., Guideline of transthyretin-related hereditary amyloidosis for clinicians, Orphanet J Rare Dis, 8, 1, pp. 1-18, (2013)
  5. Tarasoutchi F., Et al., Update of the Brazilian guidelines for valvular heart disease - 2020, Arq Bras Cardiol, 115, 4, (2020)
  6. Mesquita E.T., Et al., Cardiac amyloidosis and its new clinical phenotype: Heart failure with preserved ejection fraction, Arq Bras Cardiol, 109, 1, (2017)
  7. Chamarthi B., Et al., Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis, Am J Cardiol, 80, 9, (1997)
  8. Marin-Acevedo J.A., Sanchez-Alvarez C., Alsaad A.A., Pagan R.J., Recurrent syncope, a clue in amyloid cardiomyopathy, Case Rep Med, (2018)
  9. Donnellan E., Et al., Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis, Am J Cardiol, (2020)
  10. Donnellan E., Et al., Atrial fibrillation in transthyretin cardiac amyloidosis: Predictors, prevalence, and efficacy of rhythm control strategies, JACC Clin Electrophysiol, 6, 9, (2020)
  11. Nicol M., Et al., Thromboembolism and bleeding in systemic amyloidosis: A review, ESC Heart Failure, 9, 1, (2022)
  12. Connors L.H., Et al., Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amy-loidosis, Am Heart J, 158, 4, (2009)
  13. Suhr O.B., Et al., Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy, Amyloid, 13, 3, (2006)
  14. Dahiya D.S., Et al., Gastrointestinal amyloidosis: A focused review, World J Gastrointest Endosc, 13, 1, (2021)
  15. Cuddy S.A.M., Falk R.H., Amyloidosis as a systemic disease in context, Can J Cardiol, 36, 3, (2020)
  16. Quarta C.C., Et al., Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis, Circulation, 129, 18, (2014)
  17. Kyle R.A., Gertz M.A., Primary systemic amyloidosis: Clinical and laboratory features in 474 cases, Semin Hematol, 32, 1, (1995)

Coleções
Livros e Capítulos de Livros - HC/InCor
Livros e Capítulos de Livros - LIM/11